Komori
Governance4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

[Second Half] Integrated Report “ASKA_HD_REPORT_2025”

For fiscal 2025, the company reorganized its materiality topics from the previous 11 to 6 and newly added respect for human rights. On governance, it increased the number of independent outside directors to 4 and began considering a change in organizational structure to a company with an audit and supervisory committee.

Worth reading
91Important
Scored from 1 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Governance structure

Number of independent officers4Number

This is the number of people reported to the exchange as independent officers. Whether someone is an outside officer and whether they qualify as independent are separate determinations.

Committee1
グループ指名報酬委員会:社外委員3名/3名(100%)
Changes this time

2025年度にマテリアリティを11項目から6項目へ再編し、人権の尊重を新たに追加。独立社外取締役を4名に増員し、監査等委員会設置会社への機関設計変更の検討を開始。グループ指名報酬委員会は3名全員が社外取締役。

Governance structure
ItemDetails
Number of independent officers4 (independent outside directors)
Committeeグループ指名報酬委員会:社外委員3名/3名(100%)
Changes this time2025年度にマテリアリティを11項目から6項目へ再編し、人権の尊重を新たに追加。独立社外取締役を4名に増員し、監査等委員会設置会社への機関設計変更の検討を開始。グループ指名報酬委員会は3名全員が社外取締役。
Items this document does not state (5)
Corporate Governance StructureNumber of directorsPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

効率化と集約を進めるとともに、企業の持続的な成長と信頼構築に不可欠な人権の尊重を追加したため。機関設計変更の検討理由は本文では明示されていない。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
[Second Half] Integrated Report “ASKA_HD_REPORT_2025” | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori